June 2021-Biogen was approved for Aducanumab, a drug to reduce amyloid plaques in Alzheimer's patients.  We hoped they would go for the "one-two punch" and use Gosuranemab for tau reduction. Unfortunately, they did not see a clinical response in Alzheimer's and stopped production.  We were devastated!  Fortunately, they gave Don medication through June 2023.

​

At the same time, Congress enacted the William M. Thornberry National Defense Authorization Act.  This new law added Parkinsoisms to the list of Agent Orange presumptions.  We filed an appeal for Don's case to the VA and waited...due to Covid, the VA was back-logged, and nothing happened...In June 2022, he was denied because he was stationed in Udorn, Thailand.